Skip to main content
. 2002 May;53(5):501–507. doi: 10.1046/j.1365-2125.2002.01588.x

Table 2.

Estimates of the mean areas under the curve of the intravenous and intranasal formulations and mean bioavailability of the intranasal formulation from noncompartmental analysis for midazolam and 1-hydroxymidazolam. Values are mean±s.d.

Parameter Midazolam 1-Hydroxymidazolam
AUCi.v. (mg l−1 min) 13.0±4.7 1.76±0.61
AUCi.n. (mg l−1 min) 10.2±3.3 1.27±0.43
FAUC 0.80±0.19 0.79±0.41